trial · primary record
MK-1045
Acute Lymphoblastic Leukemia
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 203 |
| Primary completion | 2028-12-31 |
| Primary endpoint | Dose Escalation Phase: Number of Participants who Experience at Least One Adverse Event (AE) |
| Registry ID | NCT05579132 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:40.631Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05579132
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Mk-1045 · compound